Clinical Efficacy Of Infliximab Upon Crohn's Disease

Objective:We observed the clinical efficacy of the 9 patients with Crohn's disease(CD) in our hospital who received infliximab treatment for CD.Method:Retrospective analysis of CD patients with infliximab treatment in 9 cases (4 cases of CD with fistula,1 case of steroid-dependent CD and 4 cases of moderate active CD in patients). They were received 5 mg/kg intravenous infliximab at 0.2,6 weeks for the induction therapy, and then followed by every 8 weeks 5mg/kg intravenous infliximab for maintenance treatment.Then observed the clinical symptom,laboratory marker and the quality of life to evaluate the clinical efficacy of infliximab.Results:(1) 3 cases with fistula CD patients in the infliximab treatment reduced exudate of fistula,and responsed well,lease of steroid-dependent CD achieved remission after induction therapy,4 patients with moderate CD achieved clinical response in the treatment. (2)The CD patients whose CRP> 10mg/L were observed the reducing of CRP after infliximab treatment.(3)The 8 CD patients have achieved a increase of the quality of life after the infliximab treatment.Conclusion:Infliximab induction and maintenance therapy reduced exudate of fistula in the CD patients with fistula, while it induced the remission of steroid-dependent CD, and is effective for the treatment of moderate CD.